HUMAN GENOME SCIENCES INC
424B3, 2000-05-02
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: HARRYS FARMERS MARKET INC, 10-K405, 2000-05-02
Next: LEE THOMAS H, 13F-HR, 2000-05-02



<PAGE>   1

PROSPECTUS SUPPLEMENT NO. 4                     Filed Pursuant to Rule 424(b)(3)
(to Prospectus dated April 3, 2000)                   Registration No. 333-33252

                           HUMAN GENOME SCIENCES, INC.

                              --------------------

                                  $225,000,000

                   5% Convertible Subordinated Notes Due 2007

                                       and

                        2,000,000 Shares of Common Stock

                      Issuable Upon Conversion of the Notes

                              --------------------


                        The following information supplements information
            contained in our prospectus dated April 3, 2000, relating to the
            potential offer and sale from time to time by holders of the notes
            and the underlying shares of our common stock. See "Plan of
            Distribution" in our prospectus.

                        This prospectus supplement may only be delivered or used
            in connection with our prospectus. This prospectus supplement is
            incorporated by reference into our prospectus. Our common stock is
            listed on The Nasdaq National Market under the symbol "HGSI."

                        NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS
            APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS
            PROSPECTUS SUPPLEMENT OR THE PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY
            REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

                     Prospectus Supplement dated May 2, 2000


<PAGE>   2



            The notes were originally issued by us and sold by Credit Suisse
First Boston Corporation, as initial purchaser, in a transaction exempt from the
registration requirements of the Securities Act to persons reasonably believed
by the initial purchaser to be qualified institutional buyers or other
institutional accredited investors. Selling holders, including their
transferees, pledgees or donees or their successors, may from time to time offer
and sell any or all of the notes and common stock into which the notes are
convertible.

                              --------------------

            The following table supplements the information in our prospectus
with respect to the selling holders and the principal amounts of notes and
common stock they beneficially own that may be offered under our prospectus. The
information is based on information provided by or on behalf of the selling
holders. All information provided in this prospectus supplement is as of May 1,
2000.

            The selling holders may offer all, some or none of the notes or
common stock into which the notes are convertible. Thus, we cannot estimate the
amount of the notes or the common stock that will be held by the selling holders
upon termination of any sales. The column showing ownership after completion of
the offering assumes that the selling holders will sell all of the securities
offered by this prospectus supplement. In addition, the selling holders
identified below may have sold, transferred or otherwise disposed of all or a
portion of their notes since the date on which they provided the information
about their notes in transactions exempt from the registration requirements of
the Securities Act. None of the selling holders has had any material
relationship with us or our affiliates within the past three years. No selling
holder named in the table below beneficially owns one percent or more of our
common stock. Common stock owned prior to the offering and after completion of
the offering includes shares of common stock issuable upon conversion of our
5 1/2% Convertible Subordinated Notes Due 2006 and 3 3/4% Convertible
Subordinated Notes Due 2007.

<TABLE>
<CAPTION>
                                                                                                                 COMMON STOCK OWNED
                                   PRINCIPAL AMOUNT OF NOTES       COMMON STOCK OWNED PRIOR      COMMON STOCK    AFTER COMPLETION OF
NAME                             BENEFICIALLY OWNED AND OFFERED        TO THE OFFERING             OFFERED         THE OFFERING
- -----                            ------------------------------        ---------------           ------------     ----------------
<S>                                   <C>                              <C>                     <C>                 <C>
Forestal Funding Master Trust .         $  7,000,000                        62,222                  62,222               --
Sage Capital ..................            1,150,000                        14,788                  10,222               4,566
                                        ---------------                  ------------            ------------       ----------

   Total.......................         $  8,150,000                        77,010                  72,444               4,566
                                        ===============                  ============            ============       ==========
</TABLE>

            Information concerning the selling holders may change from time to
time and any changed information will be set forth in future prospectus
supplements if and when necessary. Further, the per share conversion price, and
therefore the number of shares of common stock issuable upon conversion of the
notes, is subject to adjustment. As a result, the number of shares of common
stock into which the notes are convertible may increase or decrease.


                                      S - 1






© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission